Brokerage firm Nuvama expects Kilpest India to sustain healthy growth in the molecular diagnostics business, led by product launches, acquisition of new customers, and geographical expansion. The brokerage has a “buy” rating on the stock with a price target of Rs 1,184. This implies an upside potential of 57% from the current levels.
/PRNewswire/ The "In Vitro Diagnostics Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com s offering. The global.
/PRNewswire/ According to Arizton s latest research report, the in-vitro diagnostics market will grow at a CAGR of 3.3% from 2022-2028. In recent years, IVD.